Please ensure Javascript is enabled for purposes of website accessibility

Teva Pharmaceutical Indicted on Charges of Generic Drugs Price-Fixing

By Eric Volkman – Aug 26, 2020 at 11:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is hit with three charges in the DOJ's ongoing probe; penalties could total hundreds of millions of dollars.

The U.S. Department of Justice announced late Tuesday that Teva Pharmaceutical (TEVA 1.07%) has been charged with three counts of conspiring to fix prices of generic drugs, among other crimes.

The Justice Department alleges that Teva took part in three conspiracies intending to "fix prices, rig bids and allocate customers" for such goods. It did so in collusion with peer companies active in the manufacture, sale, and distribution of generic drugs, the DOJ charges. The affected medications included cholesterol drug pravastatin, in addition to numerous other drugs that treat afflictions such as arthritis, blood clots, and hypertension.

Stethescope and gavel on desk with caduceus ornament and books

Image source: Getty Images.

Teva is the seventh company to be charged in the ongoing federal investigation. Five of those cases were resolved with deferred prosecution agreements, and one is yet to go to trial.

"Today's charges, the latest in a series of law enforcement actions taken against large drug companies, confirm that this kind of criminal behavior in the generic pharmaceutical industry will not be tolerated," said James Dawson, the acting assistant director in charge of the FBI's field office.

Tuesday night, Teva issued a press release stating, "The Company has been investigating this matter for over four years and has concluded that Teva did not participate in price fixing. Based on our internal review, Teva firmly rejects the allegations and will vigorously defend the Company in court." It added that it has cooperated fully with the DOJ's investigation.

The statutory maximum penalty for each charge is $100 million. However, this amount can go much higher based on the gain from the transgressions, or by the financial loss suffered by their victims.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.